Whistleblower Receives $8.4M for Exposing Illegal Kickback Scheme

A former pharmaceutical sales representative just received $8.4 million for doing something most people are too afraid to do: telling the truth about her employer.

Patricia Frattasio, a former sales representative at Biohaven Pharmaceutical Holding Company Ltd., filed a federal whistleblower lawsuit alleging that Biohaven ran an illegal scheme to bribe healthcare providers into prescribing its migraine drug, Nurtec ODT. Her courage triggered a federal investigation that culminated in a $59.7 million settlement—one of the more significant pharmaceutical fraud resolutions in recent years.

The case raises uncomfortable but necessary questions about the relationship between pharmaceutical companies and the doctors who prescribe their products. And for anyone with inside knowledge of corporate fraud, it offers a powerful example of what whistleblower protections can make possible.

What Biohaven Actually Did

From March 1, 2020 through September 30, 2022, Biohaven ran what the U.S. Department of Justice described as a systematic kickback operation disguised as an educational speaker program.

Here’s how it worked: Biohaven selected certain healthcare providers to join its “Nurtec ODT speaker bureau.” These providers received paid speaking opportunities—honoraria that, in some cases, amounted to tens of thousands of dollars, and in others exceeded one hundred thousand dollars. On paper, the arrangement looked legitimate. Physicians were being compensated to educate their peers about a new migraine medication.

The reality was different. The government alleged that many of these speaker programs offered no genuine educational value. Physicians who had already attended a program on the same topic attended again—and again—collecting additional honoraria without learning anything new. Some programs were attended by the speakers’ own spouses, family members, friends, and colleagues from their own medical practices. People with no professional reason to be there.

Beyond the honoraria, Biohaven paid for expensive meals and drinks at high-end restaurants. The government’s position was clear: these weren’t educational events. They were financial inducements designed to ensure that participating physicians kept writing prescriptions for Nurtec ODT.

Under the Anti-Kickback Statute—a federal law specifically designed to prevent financial incentives from corrupting medical judgment—this conduct was illegal. The statute prohibits offering or paying anything of value to induce referrals for items or services covered by Medicare, Medicaid, TRICARE, and other federal health care programs. Biohaven’s conduct, the government alleged, caused false claims to be submitted to all of these programs.

Biohaven denies the allegations. The settlement is not an admission of liability.

Pfizer acquired Biohaven in October 2022 and terminated the Nurtec speaker programs shortly thereafter. The settlement, however, covers Biohaven’s conduct before that acquisition—conduct that Pfizer, as Biohaven’s successor, agreed to pay for.

The Whistleblower Who Made It Happen

None of this enforcement action would have happened without Patricia Frattasio.

Working as a sales representative inside Biohaven, Frattasio had a front-row view of how the company operated. On August 5, 2021, she made the decision to act—filing a qui tam lawsuit in the United States District Court for the Western District of New York under the whistleblower provisions of the False Claims Act.

A qui tam action allows a private individual to file a lawsuit on behalf of the federal government, alleging that a company has defrauded it. The case is initially filed under seal, meaning it remains confidential while the government investigates. If the government intervenes and recovers money, the whistleblower receives a share—typically between 15 and 30 percent of the federal recovery.

Frattasio’s share came to approximately $8,410,166.84. That figure reflects both the scale of the fraud she exposed and the strength of the information she provided.

“Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical judgment, and not as a result of financial incentives from pharmaceutical companies,” said U.S. Attorney Trini E. Ross for the Western District of New York following the settlement announcement.

It’s a statement that cuts to the heart of why the Anti-Kickback Statute exists—and why whistleblowers like Frattasio matter.

The Settlement Breakdown

The $59,746,277 settlement was divided between federal and state programs:

• $50.2 million was recovered for the federal government, covering Medicare, TRICARE, and other federal health programs
• $9.5 million went to state Medicaid programs
• $8.4 million was paid to Patricia Frattasio as her whistleblower share of the federal recovery

Acting Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division emphasized the broader enforcement message: “Through this settlement and others, the government has demonstrated its commitment to ensuring that drug companies do not use kickbacks to influence physician prescribing. The department will use every tool at its disposal to prevent pharmaceutical manufacturers from undermining the objectivity of treatment decisions by health care providers.”

Deputy Inspector General Christian J. Schrank of HHS-OIG added that violations of the Anti-Kickback Statute “can unduly influence prescribers and negatively impact taxpayer-funded health care.”

What This Case Means for Healthcare and Compliance

The Biohaven settlement is not an isolated event. It fits into a pattern of aggressive federal enforcement against pharmaceutical companies that use financial incentives to drive prescriptions—and it sends a clear message to the industry.

For healthcare companies, the consequences of Anti-Kickback Statute violations extend well beyond the settlement check. There is reputational damage, regulatory scrutiny, and the operational disruption of a federal investigation. For executives and compliance officers, this case is a reminder that internal speaker programs require genuine educational oversight—not just the appearance of it.

For patients, the implications are more personal. When a physician’s prescribing behavior is influenced by financial incentives rather than clinical evidence, patients may end up on medications that aren’t the best choice for them. That’s not a hypothetical concern. It’s exactly what the Anti-Kickback Statute was designed to prevent.

The Power of Whistleblower Protections

What made this case possible was a legal framework built specifically to empower people in Patricia Frattasio’s position.

The False Claims Act, first signed into law by President Abraham Lincoln in 1863, remains one of the federal government’s most effective tools against fraud. Its qui tam provisions allow private individuals—including employees who witness fraud from the inside—to bring lawsuits on the government’s behalf and share in any recovery.

Whistleblowers in False Claims Act cases can receive between 15 and 30 percent of the total recovery. In large pharmaceutical fraud cases, that can translate into life-changing sums. But the financial reward is only part of the picture.

The law also provides meaningful protections against employer retaliation. Employees who are discharged, demoted, suspended, harassed, or otherwise discriminated against for filing a qui tam action have legal recourse—including reinstatement, double back pay, and attorneys’ fees.

That protection matters. Coming forward against an employer—especially a major pharmaceutical company—is not a decision anyone takes lightly. The risks are real. So is the value of having experienced legal counsel to guide the process.

Speaking Up Has Consequences—Good Ones

Patricia Frattasio’s decision to file a qui tam lawsuit exposed a scheme that was quietly distorting medical prescribing decisions and defrauding federal health programs. Her action resulted in a $59.7 million recovery for the government, an $8.4 million award for herself, and—perhaps most importantly—the termination of the speaker programs that were at the center of the fraud.

That’s what whistleblower enforcement looks like when it works.

If you have firsthand knowledge of fraud against the federal government—in healthcare, defense contracting, or any other industry—you may have the right to file a qui tam lawsuit and receive a share of any recovery. The process is confidential. The protections are real. And the potential impact, as this case shows, can be significant.

Helmer Friedman LLP’s whistleblower attorneys have the experience to guide you through every step of the False Claims Act process. Contact us today for a confidential consultation.